Azd-7762

Azd-7762

SCHEMBL1127337

NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1.O=C(O)/C=C/C(=O)O

nearest known ligand 0.92

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CHEK1

The experimentally established mechanism targets of Azd-7762. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 known ✓ O14757 18/20 0.92
MELK Q14680 3/20 0.92
PLK4 O00444 1/20 0.92
GAK O14976 1/20 0.92
JAK2 O60674 1/20 0.92
ULK1 O75385 1/20 0.92
RPS6KA4 O75676 1/20 0.92
STK10 O94804 1/20 0.92
PRKD3 O94806 1/20 0.92
MAP4K4 O95819 1/20 0.92
PAK4 O96013 1/20 0.92
ABL1 P00519 1/20 0.92
EGFR P00533 1/20 0.92
LCK P06239 1/20 0.92
FYN P06241 1/20 0.92
FES P07332 1/20 0.92
YES1 P07947 1/20 0.92
LYN P07948 1/20 0.92
RET P07949 1/20 0.92
HCK P08631 1/20 0.92

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Azd-7762 SCHEMBL31517325 0.96 CHEK1 (1.00) CHEK1MELKPLK4GAKJAK2
Azd-7762 SCHEMBL1564574 0.96 CHEK1 (1.00) CHEK1MELKPLK4GAKJAK2
Azd-7762 SCHEMBL29388936 0.96 CHEK1 (1.00) CHEK1MELKPLK4GAKJAK2
Azd-7762 SCHEMBL15105420 0.96 CHEK1 (1.00) CHEK1MELKPLK4GAKJAK2
Azd-7762 SCHEMBL1127614 0.96 CHEK1 (1.00) CHEK1MELKPLK4GAKJAK2
Azd-7762 SCHEMBL19457662 0.95 MELK (1.00) CHEK1MELKPLK4GAKJAK2
Azd-7762 SCHEMBL29994838 0.95 MELK (1.00) CHEK1MELKPLK4GAKJAK2
SCHEMBL31532638 0.93 CHEK1 (0.95) CHEK1MELKPLK4GAKJAK2
SCHEMBL31532541 0.93 CHEK1 (0.95) CHEK1MELKPLK4GAKJAK2
SCHEMBL31532634 0.90 CHEK1 (0.89) CHEK1MELKPLK4GAKJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110112144-A1 METHODS OF PREPARING SUBSTITUTED HETEROCYCLES ASTRAZENECA AB (SE) 2011-05-12 US disclosed
EP-2283012-A1 METHODS OF PREPARING SUBSTITUTED HETEROCYCLES AstraZeneca AB (SE) 2011-02-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112144-A1 METHODS OF PREPARING SUBSTITUTED HETEROCYCLES HCCS, DPYD, TYMP CHEK1 80/4885MELK 3335/4885PLK4 2749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.